John Marotta
Appointed CEO Marotta at Azenta Life Sciences is anticipated to reduce expenses but is doubted on growth delivery due to a poor performance history.
Sources highlight Marotta’s solid strategic and financial expertise but note execution and leadership weaknesses, resulting in varied opinions from past associates.
Marotta’s pattern of brief roles and underwhelming results casts uncertainty on his ability to boost Azenta’s sales, implying a likely emphasis on cutting costs.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.